Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme
- PMID: 23593382
- PMCID: PMC3622606
- DOI: 10.1371/journal.pone.0061035
Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme
Abstract
Patients with primary glioblastoma multiforme (GBM) have one of the lowest overall survival rates among cancer patients, and reliable biomarkers are necessary to predict patient outcome. Cytochrome c oxidase (CcO) promotes the switch from glycolytic to OXPHOS metabolism, and increased CcO activity in tumors has been associated with tumor progression after chemotherapy failure. Thus, we investigated the relationship between tumor CcO activity and the survival of patients diagnosed with primary GBM. A total of 84 patients with grade IV glioma were evaluated in this retrospective cohort study. Cumulative survival was calculated by the Kaplan-Meier method and analyzed by the log-rank test, and univariate and multivariate analyses were performed with the Cox regression model. Mitochondrial CcO activity was determined by spectrophotometrically measuring the oxidation of cytochrome c. High CcO activity was detected in a subset of glioma tumors (∼30%), and was an independent prognostic factor for shorter progression-free survival and overall survival [P = 0.0087 by the log-rank test, hazard ratio = 3.57 for progression-free survival; P<0.001 by the log-rank test, hazard ratio = 10.75 for overall survival]. The median survival time for patients with low tumor CcO activity was 14.3 months, compared with 6.3 months for patients with high tumor CcO activity. High CcO activity occurs in a significant subset of high-grade glioma patients and is an independent predictor of poor outcome. Thus, CcO activity may serve as a useful molecular marker for the categorization and targeted therapy of GBMs.
Conflict of interest statement
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3622606/bin/pone.0061035.g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3622606/bin/pone.0061035.g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3622606/bin/pone.0061035.g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3622606/bin/pone.0061035.g004.gif)
Similar articles
-
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.Neurooncol Adv. 2021 Dec 24;4(1):vdab186. doi: 10.1093/noajnl/vdab186. eCollection 2022 Jan-Dec. Neurooncol Adv. 2021. PMID: 35088051 Free PMC article.
-
Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.J Biol Chem. 2016 Nov 11;291(46):24188-24199. doi: 10.1074/jbc.M116.749978. Epub 2016 Sep 27. J Biol Chem. 2016. PMID: 27679486 Free PMC article.
-
Cytochrome c oxidase mediates labile iron level and radioresistance in glioblastoma.Free Radic Biol Med. 2022 May 20;185:25-35. doi: 10.1016/j.freeradbiomed.2022.04.012. Epub 2022 Apr 25. Free Radic Biol Med. 2022. PMID: 35476930
-
A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord.J Neurosurg Pediatr. 2017 Feb;19(2):239-248. doi: 10.3171/2016.8.PEDS1631. Epub 2016 Nov 4. J Neurosurg Pediatr. 2017. PMID: 27813458 Review.
-
Primary and metastatic glioblastoma of the spine in the pediatric population: a systematic review.Childs Nerv Syst. 2021 Jun;37(6):1849-1858. doi: 10.1007/s00381-021-05098-8. Epub 2021 Mar 6. Childs Nerv Syst. 2021. PMID: 33675391 Review.
Cited by
-
Glioblastoma Metabolism: Insights and Therapeutic Strategies.Int J Mol Sci. 2023 May 23;24(11):9137. doi: 10.3390/ijms24119137. Int J Mol Sci. 2023. PMID: 37298093 Free PMC article. Review.
-
Mitoferrin-1 Promotes Proliferation and Abrogates Protein Oxidation via the Glutathione Pathway in Glioblastoma.Antioxidants (Basel). 2023 Feb 1;12(2):349. doi: 10.3390/antiox12020349. Antioxidants (Basel). 2023. PMID: 36829908 Free PMC article.
-
Proton pump inhibitors display anti-tumour potential in glioma.Cell Prolif. 2023 Jul;56(7):e13321. doi: 10.1111/cpr.13321. Epub 2022 Aug 12. Cell Prolif. 2023. PMID: 35961680 Free PMC article. Review.
-
High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma.Dis Markers. 2022 Apr 21;2022:8133505. doi: 10.1155/2022/8133505. eCollection 2022. Dis Markers. 2022. PMID: 35493303 Free PMC article.
-
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.Neurooncol Adv. 2021 Dec 24;4(1):vdab186. doi: 10.1093/noajnl/vdab186. eCollection 2022 Jan-Dec. Neurooncol Adv. 2021. PMID: 35088051 Free PMC article.
References
-
- Hegi ME, Liu L, Herman JG, Stupp R, Wick W, et al. (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189–4199. - PubMed
-
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996. - PubMed
-
- Huttemann M, Muhlenbein N, Schmidt TR, Grossman LI, Kadenbach B (2000) Isolation and sequence of the human cytochrome c oxidase subunit VIIaL gene. Biochim Biophys Acta 1492: 252–258. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR000165/TR/NCATS NIH HHS/United States
- R01CA160821/CA/NCI NIH HHS/United States
- R01GM096191/GM/NIGMS NIH HHS/United States
- P20 CA151129/CA/NCI NIH HHS/United States
- HHSN261200800001C/CA/NCI NIH HHS/United States
- 261200800001E/PHS HHS/United States
- R01 GM096191/GM/NIGMS NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
- R21CA139290/CA/NCI NIH HHS/United States
- R01 CA160821/CA/NCI NIH HHS/United States
- UL1TR000165/TR/NCATS NIH HHS/United States
- P50 CA097247/CA/NCI NIH HHS/United States
- R21 CA139290/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical